Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
$1.33−0.07 (-5.34%)
Close on Nov 17, 2026Market cap $124.65MP/E –Yield –
Innate Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -€54.01M. The highest annual figure on record is €5.15M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€54.01M | – |
| FY2024 | Dec 31, 2024 | -€51.58M | – |
| FY2023 | Dec 31, 2023 | -€12.67M | – |
| FY2022 | Dec 31, 2022 | -€57.43M | – |
| FY2021 | Dec 31, 2021 | -€47.83M | -4532.3% |
| FY2020 | Dec 31, 2020 | €1.08M | -31.5% |
| FY2019 | Dec 31, 2019 | €1.58M | -69.4% |
| FY2018 | Dec 31, 2018 | €5.15M | – |
| FY2017 | Dec 31, 2017 | -€39.98M | – |
See a number that looks wrong?